PART I Overview OnKure Therapeutics, Inc. (OnKure, we, us or the Company) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tol...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104147 | EDGAR | 103K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-036252 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038009 | EDGAR | — |
| 2023-03-27 | 2022-12-31 | 0000950170-23-009978 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001558370-22-004158 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269540 | EDGAR | 60K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178981 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063970 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123233 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096411 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054452 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062910 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041302 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021234 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023250 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016035 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001558370-22-008103 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-130283 | EDGAR | 20K words |
| 2026-03-12 | 0001193125-26-104104 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269652 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269468 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178978 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090403 | EDGAR | — |
| 2025-05-28 | 0000950170-25-078375 | EDGAR | — |
| 2025-05-06 | 0000950170-25-063969 | EDGAR | — |
| 2025-03-10 | 0000950170-25-036306 | EDGAR | — |
| 2024-12-10 | 0000950170-24-134757 | EDGAR | — |
84 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001637715 |
| Ticker | OKUR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.onkuretherapeutics.com |
| Listed | 2024-10-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report